Emerging market

Aristotle Pacific Capital Further Expands Investment Team

Retrieved on: 
Wednesday, January 17, 2024
Finance, Data Analytics, Banking, Professional Services, Asset Management, Emerging market, Credit analyst, Multimedia, CFA, Berea College, PIMCO, University, Metal, MBA, Investment, Jadavpur University, Master of Quantitative Finance, BNP Paribas, Car, Mathematics, Management, Security (finance)

Aristotle Pacific Capital, LLC (“Aristotle Pacific”), a leader in liquid credit investments, announced the further expansion of its investment team with the appointment of two seasoned investment professionals.

Key Points: 
  • Aristotle Pacific Capital, LLC (“Aristotle Pacific”), a leader in liquid credit investments, announced the further expansion of its investment team with the appointment of two seasoned investment professionals.
  • Norvruz (Novi) Bashirov joined Aristotle Pacific as Managing Director, Portfolio Manager & Senior Research Analyst and Partha Bose, CFA, joined as a Senior Research Analyst.
  • View the full release here: https://www.businesswire.com/news/home/20240117064412/en/
    “Given the current opportunities in the corporate credit landscape and wide demand for our strategies, expanding our investment team with seasoned professionals broadens our ability to provide more value to our clients,” said Dominic Nolan, Chief Executive Officer of Aristotle Pacific.
  • Prior to joining Rimrock Capital, he co-managed funds at Barings’ Emerging Markets Corporate Group and managed Emerging Markets portfolios at PIMCO.

Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

Retrieved on: 
Thursday, January 25, 2024
Patient, Medication, Emerging market, GSSA, Action Replay, Microsatellite, MSI-H, Chinese, MFS, CIS, Cholangiocarcinoma, UPS, Cancer, License, PD-L1, STS, Lung cancer, Neoplasm, Prevalence, Myxofibrosarcoma, National Medical Products Administration, LTD, NMPA

Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.

Key Points: 
  • Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.
  • 3D Medicines retains the right to develop and commercialize Envafolimab for any purpose outside the Territory.
  • Under the terms of the agreement, GSSA will receive from Jiangsu Alphamab and 3D Medicines, an exclusive license to develop, register, commercialize, Envafolimab for the oncology indication in the Territory.
  • The Licensors' respective entitlement to the payments (including the upfront payment, milestone payment and the royalty fees) under the License Agreement are subject to the agreements between 3D Medicines and Jiangsu Alphamab.

Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

Retrieved on: 
Thursday, January 25, 2024
Patient, Medication, Emerging market, GSSA, Action Replay, Microsatellite, MSI-H, Chinese, MFS, CIS, Cholangiocarcinoma, UPS, Cancer, License, PD-L1, STS, Lung cancer, Neoplasm, Prevalence, Myxofibrosarcoma, National Medical Products Administration, LTD, NMPA

Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.

Key Points: 
  • Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.
  • 3D Medicines retains the right to develop and commercialize Envafolimab for any purpose outside the Territory.
  • Under the terms of the agreement, GSSA will receive from Jiangsu Alphamab and 3D Medicines, an exclusive license to develop, register, commercialize, Envafolimab for the oncology indication in the Territory.
  • The Licensors' respective entitlement to the payments (including the upfront payment, milestone payment and the royalty fees) under the License Agreement are subject to the agreements between 3D Medicines and Jiangsu Alphamab.

Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

Retrieved on: 
Thursday, January 25, 2024
Patient, Medication, Emerging market, GSSA, Action Replay, Microsatellite, MSI-H, Chinese, MFS, CIS, Cholangiocarcinoma, UPS, Cancer, License, PD-L1, STS, Lung cancer, Neoplasm, Prevalence, Myxofibrosarcoma, National Medical Products Administration, LTD, NMPA

Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.

Key Points: 
  • Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.
  • 3D Medicines retains the right to develop and commercialize Envafolimab for any purpose outside the Territory.
  • Under the terms of the agreement, GSSA will receive from Jiangsu Alphamab and 3D Medicines, an exclusive license to develop, register, commercialize, Envafolimab for the oncology indication in the Territory.
  • The Licensors' respective entitlement to the payments (including the upfront payment, milestone payment and the royalty fees) under the License Agreement are subject to the agreements between 3D Medicines and Jiangsu Alphamab.

Santander, Ramirez & Co. and Mischler Financial Group Join DirectBooks

Retrieved on: 
Wednesday, January 24, 2024
Emerging market, Mischler Financial Group, Security (finance)

NEW YORK and LONDON, Jan. 24, 2024 /PRNewswire/ -- DirectBooks, a global leader in primary markets communications, announced today that Santander, Ramirez & Co. and Mischler Financial Group have joined the platform. The recent additions increase the number of underwriters participating on DirectBooks to 34 worldwide.

Key Points: 
  • NEW YORK and LONDON, Jan. 24, 2024 /PRNewswire/ -- DirectBooks , a global leader in primary markets communications, announced today that Santander, Ramirez & Co. and Mischler Financial Group have joined the platform.
  • The recent additions increase the number of underwriters participating on DirectBooks to 34 worldwide.
  • "DirectBooks welcomes our newest members as we continue to fulfill our goal of broadening our global community of underwriters," said DirectBooks CEO, Rich Kerschner.
  • In 2023, DirectBooks celebrated a community growth milestone by surpassing 500 institutional investor accounts.

Fusemachines Inc. to List on NASDAQ Through Business Combination with CSLM Acquisition Corp.

Retrieved on: 
Tuesday, January 23, 2024
PIPE, Research, Associate, Enterprise, Emerging market, Face, AI, OTG, TIME, Acquisition, Columbia University, IBM Watson, ROI

, a leading provider of enterprise AI products and solutions and CSLM Acquisition Corp.(NASDAQ: CSLM), a special purpose acquisition company, announced today the signing of a definitive agreement for a business combination that is expected to result in Fusemachines becoming a public company.

Key Points: 
  • , a leading provider of enterprise AI products and solutions and CSLM Acquisition Corp.(NASDAQ: CSLM), a special purpose acquisition company, announced today the signing of a definitive agreement for a business combination that is expected to result in Fusemachines becoming a public company.
  • Upon the closing of the transaction, subject to approvals by CSLM's stockholders and Fusemachines stockholders and other customary closing conditions, the combined company is expected to list on Nasdaq under the ticker symbol "FUSE".
  • The business combination, valuing the combined company at $200 million, is expected to be completed by the end of Q2 2024.
  • "Our business combination with CSLM positions us to strategically lead the way in shaping the future of democratizing AI and leaving a lasting impact across industries.

Porsche posts stable sales in 2023: strong growth for the 911 and Taycan

Retrieved on: 
Saturday, January 13, 2024
Porsche Macan, Porsche Panamera, Emerging market, SUV, Macan, Porsche Boxster/Cayman, Overseas, Marketing, Growth, Retail

Porsche posts stable sales in 2023: strong growth for the 911 and Taycan

Key Points: 
  • Porsche posts stable sales in 2023: strong growth for the 911 and Taycan
    Stuttgart.
  • Porsche saw robust growth in the 2023 fiscal year and posted a slight gain in deliveries.
  • The Porsche 911 recorded the largest increase of all model lines in 2023, with an increase of 24 per cent.
  • In 2024 we will focus more than ever on value-oriented growth and a stable sales level."

Matthews Launches New Discovery Active ETFs Focused on Smaller Companies With Innovative and Entrepreneurial Business Models

Retrieved on: 
Thursday, January 11, 2024
ETF, Research, Heart, Emerging market, SAN, CFA, Discovery, Radar, MEMS, MCHS, Growth, Renewable energy

SAN FRANCISCO, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Matthews introduced two new active ETFs, the Matthews Emerging Markets Discovery Active ETF (MEMS) and the Matthews China Discovery Active ETF (MCHS) on the Nasdaq Stock Exchange today, adding the ‘power of choice’ for investors to the firm’s active ETF suite of 12 funds.

Key Points: 
  • SAN FRANCISCO, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Matthews introduced two new active ETFs, the Matthews Emerging Markets Discovery Active ETF (MEMS) and the Matthews China Discovery Active ETF (MCHS) on the Nasdaq Stock Exchange today, adding the ‘power of choice’ for investors to the firm’s active ETF suite of 12 funds.
  • Through active, in-depth fundamental research and considered portfolio construction, Matthews believes smaller companies in Emerging Markets may offer a compelling investment opportunity, while providing diversification.
  • Our Discovery Active ETFs leverage Matthews’ deep expertise in smaller companies that can potentially provide more exposure to new business models, domestic markets, and innovative companies that can be growing quickly.
  • Matthews Discovery Active ETFs give investors differentiated exposures to potentially under-researched companies typically not found in broad, larger-cap Emerging Market or international strategies.

Emerging Markets Report: Building Trust

Retrieved on: 
Tuesday, December 12, 2023
Olive, Editorial, Health care, Person, Yale University, Yale School of Medicine, Ken, Olive View–UCLA Medical Center, Artificial intelligence, Investment, Name, OTCQB, Gerber, Emerging market, Yale school

ORLANDO, Fla., Dec. 12, 2023 (GLOBE NEWSWIRE) -- It’s been a minute since we last covered Medical/A.I. company MedBright AI Investments Inc. (the “Company” or “MedBright”) (CSE:MBAI, OTCQB:MBAIF, FSE:1V7).

Key Points: 
  • In our last editorial we noted the Company’s transformation to MedBright from Vinergy, a name change that made and makes sense to us given their business model.
  • We strongly encourage you to catch-up in this dynamic, fast-moving Company by reviewing that piece .
  • At the Emerging Markets Report we are cautious and enthusiastic fans of Artificial Intelligence.
  • We believe that it will be one of the most impactful technology drivers in almost every aspect of our lives.

Veteran MedTech leader and hospital group CEO joins CMR Surgical as global Chief Commercial Officer

Retrieved on: 
Monday, December 11, 2023
Marketing, CMR, Johnson & Johnson, Medtech, Medical device, Surgeon, Hospital, GMT, CMR Surgical, Smith & Nephew, Smith, Emerging market, Growth, Patient, Pharma, Nursing

CMR Surgical (“CMR” or “the Company”), the global surgical robotics business, today announces that Massimiliano Colella has joined the Company as global Chief Commercial Officer.

Key Points: 
  • CMR Surgical (“CMR” or “the Company”), the global surgical robotics business, today announces that Massimiliano Colella has joined the Company as global Chief Commercial Officer.
  • The appointment comes as CMR accelerates its already successful installations of Versius, bringing minimal access surgery to more patients around the world.
  • Massimiliano joins CMR from Evercare Group, a leading hospital group, where he served as Group Chief Executive Officer and Board member.
  • Having led a large hospital group, the momentum and need for surgical robotics is only growing, both to bring more equity of care for patients, and to look after our surgical workforce.